Aarey Drugs

What is the bonus history of the Aarey Drugs?

Aarey Drugs & Pharmaceuticals Ltd issued a 1:5 bonus on June 25, 2012, granting shareholders one additional share for every five shares held, with a record date of June 26, 2012. This is the company's most recent bonus action.

Aarey Drugs & Pharmaceuticals Ltd has a bonus history that includes a notable issue on June 25, 2012. The company announced a 1:5 bonus issue, meaning that for every five shares held, shareholders received one additional share. The record date for this bonus was June 26, 2012. This was the most recent bonus action recorded for the company. If you have any more questions about Aarey Drugs or need further details, feel free to ask!

Has Aarey Drugs declared dividend?

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend, amounting to ₹0.10 per share, with an ex-date of December 13, 2018. Despite the dividend declaration, the dividend yield is 0%, and total returns over various periods show significant price appreciation, especially over five years.

Aarey Drugs & Pharmaceuticals Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.10<BR>- Ex-date: 13 Dec 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -12.92%, the dividend return was 0%, resulting in a total return of -12.92%.<BR><BR>For the 1 year period, the price return was 21.16%, the dividend return was 0%, leading to a total return of 21.16%.<BR><BR>Over the 2 years period, the price return was 66.72%, the dividend return was 0%, culminating in a total return of 66.72%.<BR><BR>In the 3 years period, the price return was 50.85%, the dividend return was 0%, which resulted in a total return of 50.85%.<BR><BR>For the 4 years period, the price return was 55.93%, the dividend return was 0%, yielding a total return of 55.93%.<BR><BR>In the 5 years period, the price return was 155.4%, the dividend return was 0%, resulting in a total return of 155.4%.<BR><BR>Overall, Aarey Drugs has declared a dividend, but the dividend yield remains at 0%. The total returns over various periods show a mix of performance, with significant price returns in the longer term, particularly over 5 years.

Who are the peers of the Aarey Drugs?

Aarey Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, BDH Industries, Denis Chem Lab, and Tyche Industries. Aarey Drugs has average management risk and below average growth and capital structure compared to its peers, with a 1-year return of 13.67%.

Peers: The peers of Aarey Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Smruthi Organic, BDH Industries, Denis Chem Lab, Tyche Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Tyche Industries, and the rest. Average management risk is found at Aarey Drugs and Denis Chem Lab. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen in Divi's Lab., Torrent Pharma, Smruthi Organic, BDH Industries, Aarey Drugs, Denis Chem Lab, and Tyche Industries. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, Smruthi Organic, BDH Industries, and Tyche Industries, while Aarey Drugs has a below average capital structure along with Denis Chem Lab.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Denis Chem Lab has the lowest at -38.43%. Aarey Drugs' 1-year return of 13.67% is higher than Denis Chem Lab's but lower than Divi's Lab.'s. Additionally, the six-month return is negative for BDH Industries, Denis Chem Lab, and Tyche Industries.

What is the technical trend for Aarey Drugs?

As of June 5, 2025, Aarey Drugs shows a neutral technical stance with mixed signals: weekly indicators are bullish while daily trends are mildly bearish, suggesting caution despite potential upward movement indicated by Bollinger Bands.

As of 5 June 2025, the technical trend for Aarey Drugs has changed from mildly bearish to sideways. The weekly MACD is bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The Bollinger Bands are bullish on both weekly and monthly charts, suggesting potential upward movement. However, daily moving averages are mildly bearish, which adds caution. The KST shows a bullish stance weekly but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly trend with a mildly bullish monthly outlook. Overall, the current technical stance is neutral, with strength in the weekly indicators but caution from daily trends.

Who are in the management team of Aarey Drugs?

As of March 2023, the management team of Aarey Drugs includes Mihir R Ghatalia (Chairman & Managing Director), Nimit R Ghatalia (Executive Director), and several independent directors: Chetan K Mehta, Lalit Tulsiani, and Anil Mandal, along with Preeti Paresh Rathi (Company Secretary) and Bina Ghatalia (Additional Director). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Aarey Drugs includes the following individuals:<BR><BR>1. Mihir R Ghatalia - Chairman & Managing Director<BR>2. Chetan K Mehta - Independent Director<BR>3. Preeti Paresh Rathi - Company Secretary & Compliance Officer<BR>4. Lalit Tulsiani - Independent Director<BR>5. Nimit R Ghatalia - Executive Director<BR>6. Anil Mandal - Independent Director<BR>7. Bina Ghatalia - Additional Director<BR><BR>Each member plays a distinct role within the company, contributing to its governance and operations.

What does Aarey Drugs do?

Aarey Drugs & Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, with net sales of 1,081 Cr and a net profit of 5 Cr as of March 2025. Originally incorporated as Niharika Textiles in 1990, it became a public company in 1993 under the Aarey Group.

Overview: <BR>Aarey Drugs & Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The company was originally incorporated in 1990 as Niharika Textiles & Chemicals Pvt Ltd. It underwent a status change to a public limited company in March 1993 after being taken over by the Aarey Group of companies. The latest reported quarter for sales and profit is March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,081 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 5 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 195 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 47.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.24 <BR>Return on Equity: 2.91% <BR>Price to Book: 1.41 <BR><BR>Contact Details: <BR>Address: E-34 MIDC Tarapur, Boisar Thane Maharashtra : 401506 <BR>Tel: 91-22-23455543 <BR>Website: http://www.aareydrugs.com

Who are the top shareholders of the Aarey Drugs?

The top shareholders of Aarey Drugs include promoter Bina Rajesh Ghatalia with 14.12%, and the highest public shareholder, India Opportunities Growth Fund Ltd - Pinewood, with 2.34%. Individual investors hold 45.79%, and there is one foreign institutional investor with 2.34%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Aarey Drugs include Bina Rajesh Ghatalia, who is the promoter with the highest holding at 14.12%. Additionally, the highest public shareholder is India Opportunities Growth Fund Ltd - Pinewood, holding 2.34%. The company also has individual investors holding a significant portion at 45.79%. Furthermore, there is one foreign institutional investor (FII) that holds 2.34% of the shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is Aarey Drugs?

As of 24th July, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 192.00 Cr, with recent net sales of 473.94 Cr and a net profit of 4.03 Cr. The balance sheet for March 2024 shows shareholder's funds of 132.77 Cr and total assets of 303.29 Cr.

As of 24th July, Aarey Drugs & Pharmaceuticals Ltd has a market capitalization of 192.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Aarey Drugs reported Net Sales of 473.94 Cr and a Net Profit of 4.03 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 132.77 Cr and Total Assets of 303.29 Cr.

Is Aarey Drugs overvalued or undervalued?

As of November 17, 2025, Aarey Drugs is considered overvalued with a high PE ratio of 75.88, weak profitability indicated by a 2.47% ROE, and negative operational metrics, despite recent strong stock performance.

As of 17 November 2025, Aarey Drugs has moved from a fair to a risky valuation grade. The company appears to be overvalued, primarily indicated by its high PE ratio of 75.88 and an EV to EBITDA ratio of 134.14, which are significantly above industry norms. Additionally, the return on equity (ROE) stands at a mere 2.47%, reflecting weak profitability, while the EV to EBIT ratio is notably negative at -315.22, suggesting severe operational challenges.<BR><BR>In comparison to its peers, Aarey Drugs' valuation metrics are concerning. For instance, Elitecon International has a PE ratio of 294.38, indicating a very expensive valuation, while PTC India, which is considered very attractive, has a PE of just 7.56. Aarey Drugs' high valuation ratios, combined with its negative ROCE of -0.07%, further underscore its overvaluation status. Despite recent strong stock performance against the Sensex, with a year-to-date return of 68.93% compared to the Sensex's 8.72%, the underlying financial metrics suggest that the stock may not sustain its current price levels.

How has been the historical performance of Aarey Drugs?

Aarey Drugs has experienced fluctuating financial performance, with net sales increasing to 473.94 Cr in March 2025 from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. Profitability metrics, including operating profit and earnings per share, have generally declined, indicating challenges in maintaining consistent profitability.

Answer:<BR>The historical performance of Aarey Drugs shows a fluctuating trend in net sales and profitability over the years, with net sales reaching 473.94 Cr in March 2025, up from 395.62 Cr in March 2024, but down from 492.68 Cr in March 2022. The total operating income followed a similar pattern, peaking at 492.68 Cr in March 2022 before declining to 473.94 Cr in March 2025. The operating profit (PBDIT) has also seen a decline, from 14.02 Cr in March 2022 to 12.70 Cr in March 2025. Profit before tax increased slightly to 6.10 Cr in March 2025 from 5.34 Cr in March 2024, while profit after tax decreased to 4.02 Cr in March 2025 from 4.68 Cr in March 2024. The company's earnings per share (EPS) dropped to 1.43 in March 2025 from 1.67 in March 2024, reflecting the overall decline in profitability.<BR><BR>Breakdown:<BR>Aarey Drugs' financial performance has shown variability in key metrics over the years. Net sales increased from 395.62 Cr in March 2024 to 473.94 Cr in March 2025, although this is a decrease from the 492.68 Cr recorded in March 2022. Total operating income mirrored this trend, with a peak in March 2022 before falling to 473.94 Cr in March 2025. Operating profit (PBDIT) has declined from 14.02 Cr in March 2022 to 12.70 Cr in March 2025, indicating a downward trend in profitability. Profit before tax saw a slight increase to 6.10 Cr in March 2025, while profit after tax decreased to 4.02 Cr in the same period. The earnings per share (EPS) also fell to 1.43 in March 2025 from 1.67 in March 2024, reflecting the challenges faced by the company in maintaining profitability amidst fluctuating sales and operating income.

When is the next results date for Aarey Drugs & Pharmaceuticals Ltd?

The next results date for Aarey Drugs & Pharmaceuticals Ltd is 11 February 2026.

The next results date for Aarey Drugs & Pharmaceuticals Ltd is scheduled for 11 February 2026.

Are Aarey Drugs & Pharmaceuticals Ltd latest results good or bad?

Aarey Drugs & Pharmaceuticals Ltd's latest results are concerning, showing a 44.12% decline in net profit and a 27.92% drop in revenue, marking three consecutive quarters of revenue decline and a negative operating margin. Overall, these trends indicate a deteriorating financial position for the company.

Aarey Drugs & Pharmaceuticals Ltd's latest results are concerning. In Q3 FY26, the company reported a net profit of ₹0.57 crore, which is a significant decline of 44.12% compared to the previous quarter. Revenue also fell sharply, down 27.92% year-on-year to ₹96.43 crore, marking the third consecutive quarter of revenue decline. The operating margin turned negative at -1.57%, indicating that the core business is currently unprofitable.<BR><BR>These financial trends reflect broader challenges within the pharmaceutical sector, including pricing pressures and increased competition. The company's reliance on non-operating income to sustain profitability further complicates the situation, raising questions about its operational efficiency.<BR><BR>While Aarey Drugs has delivered strong long-term returns, the recent performance suggests a troubling trajectory, with a 28.91% decline in stock price over the past three months. Overall, the latest results indicate a deteriorating financial position, making it a challenging environment for the company moving forward.

Should I buy, sell or hold Aarey Drugs & Pharmaceuticals Ltd?

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 17-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 67.03, reflecting a 6.68% increase after two days of decline. However, it remains below its moving averages, indicating potential long-term downward trends, alongside a notable decrease in investor participation.

As of 17-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 67.03, which reflects an increase of Rs 4.2 or 6.68%. This upward movement comes after a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock has outperformed its sector by 6.21% today, indicating a positive performance relative to its peers.<BR><BR>Despite this rise, it's important to note that Aarey Drugs is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests that while there is a short-term increase, the longer-term trend may still be downward. Furthermore, there has been a decrease in investor participation, with delivery volume falling by 33.79% compared to the 5-day average, which could indicate a lack of sustained interest from investors.<BR><BR>Overall, the stock's current rise can be attributed to a short-term recovery after previous declines and a strong performance relative to its sector, despite underlying concerns regarding moving averages and declining investor participation.

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 18-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 70.03, reflecting a 4.48% increase, driven by strong short-term performance and heightened investor interest. However, the company faces significant financial challenges, including operating losses and declining promoter confidence, which may affect future performance.

As of 18-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 70.03, reflecting a change of 3.0 (4.48%) upwards. This upward movement can be attributed to several factors. The stock has shown strong performance in the short term, outperforming the sector by 2.99% today and achieving a consecutive gain over the last two days with a total return of 11.46% during this period. Additionally, the stock's performance over the past week has been positive, with a return of +2.88%, contrasting with a slight decline in the benchmark Sensex by -0.21%.<BR><BR>Despite opening with a loss of -3.01% today, the stock reached an intraday high of Rs 72.9, indicating significant volatility and investor interest. The rising investor participation is notable, with delivery volume increasing by 158.94% against the 5-day average, suggesting heightened trading activity and interest in the stock.<BR><BR>However, it is important to note that the company faces challenges, including operating losses and a weak long-term fundamental strength, which could impact future performance. The company has reported negative results for the last four consecutive quarters, with net sales falling by -27.92% and a significant drop in profit before tax. Additionally, promoter confidence appears to be waning, as they have reduced their stake by -5.74% in the previous quarter.<BR><BR>In summary, while Aarey Drugs & Pharmaceuticals Ltd is currently rising in stock price due to recent gains and increased investor participation, underlying financial challenges and reduced promoter confidence may pose risks for the future.

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 19-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price has declined to Rs 67.43, down 7.04%, influenced by underperformance against its sector and a reversal after previous gains. Despite a strong yearly increase of 92.71%, recent trends indicate bearish sentiment and selling pressure among investors.

As of 19-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 67.43, which reflects a change of -5.11 (-7.04%). This drop can be attributed to several factors. Firstly, the stock has underperformed its sector by -3.43% today, indicating a weaker performance relative to its peers. Additionally, the stock has fallen after two consecutive days of gains, suggesting a trend reversal. <BR><BR>Intraday, the stock reached a low of Rs 66.09, marking a significant decline of -8.89%. The trading volume has also shown a shift, with more volume traded closer to this low price, indicating that investors may be selling off shares. Furthermore, while the stock's performance over the past year has been strong with a +92.71% increase, the recent one-month performance shows a decline of -5.93%, which may be contributing to negative sentiment among investors.<BR><BR>Moreover, the stock's moving averages indicate that it is currently higher than the 5-day moving average but lower than the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the short to medium term. Overall, these factors combined point to a decline in the stock price of Aarey Drugs & Pharmaceuticals Ltd.

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 20-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price is Rs 68.50, up 1.59%, with a recent 5.32% gain over the past week. Despite declining investor participation indicated by a 71.17% drop in delivery volume, the stock remains above its 5-day moving averages, suggesting a short-term positive trend.

As of 20-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 68.50, reflecting an increase of Rs 1.07 or 1.59%. This upward movement can be attributed to the stock's performance over the past week, where it has gained 5.32%, contrasting with the Sensex, which has remained nearly flat at -0.04%. <BR><BR>Additionally, the stock reached an intraday high of Rs 70.76, indicating strong intraday trading activity. However, it is important to note that while the stock is performing well today, there are signs of declining investor participation, as evidenced by a significant drop in delivery volume, which fell by 71.17% compared to the 5-day average. <BR><BR>Despite this decline in participation, the stock's current price is above its 5-day moving averages, suggesting a short-term positive trend. Overall, the combination of recent gains and intraday highs supports the current rise in Aarey Drugs & Pharmaceuticals Ltd's stock price.

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 23-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price has declined to Rs 62.02, down 10% due to underperformance against its sector, high volatility, trading below moving averages, and decreased investor participation. These factors collectively indicate a bearish trend and lack of confidence among investors.

As of 23-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 62.02, reflecting a change of -6.89 (-10.0%). This drop can be attributed to several factors highlighted in the data. <BR><BR>Firstly, the stock has underperformed its sector by -4.99% today, indicating a weaker performance relative to its peers. The stock also reached an intraday low of Rs 62.02, which is a significant decrease of 10%. Additionally, the stock has shown high volatility, with an intraday volatility of 5.26%, suggesting that there has been considerable fluctuation in its price throughout the trading day.<BR><BR>Furthermore, Aarey Drugs is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bearish trend. The trading volume has also decreased significantly, with a delivery volume of 25.08k on 20 March, which is down by -69.17% compared to the 5-day average. This decline in investor participation may indicate a lack of confidence among investors, contributing to the falling stock price.<BR><BR>Overall, the combination of underperformance against the sector, high volatility, trading below moving averages, and reduced investor participation are key factors driving the decline in Aarey Drugs & Pharmaceuticals Ltd's stock price.

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 24-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price has risen to Rs 63.84, up 2.92%, outperforming its sector today. Despite recent declines over the past month, increased investor participation has contributed to this price rise.

As of 24-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at Rs 63.84, which reflects an increase of Rs 1.81 or 2.92%. This upward movement is notable as the stock has outperformed its sector by 2.03% today. Additionally, the stock reached an intraday high of Rs 65.26, marking a 5.21% increase at that point.<BR><BR>Despite this positive performance today, it is important to note that the stock has been underperforming over the past week and month, with declines of 4.76% and 15.06%, respectively. However, the recent rise can be attributed to increased investor participation, as evidenced by a delivery volume of 1.15 lacs on 23 March, which is a 40.17% increase compared to the 5-day average. This suggests a growing interest in the stock, contributing to its price rise.<BR><BR>Furthermore, while Aarey Drugs is currently trading below its moving averages across various time frames, the liquidity remains adequate for trading, indicating that there is sufficient market activity to support the stock's price movement. Overall, the combination of today's performance and increased investor engagement appears to be driving the stock's rise.

Why is Aarey Drugs & Pharmaceuticals Ltd falling/rising?

As of 25-Mar, Aarey Drugs & Pharmaceuticals Ltd's stock price is Rs 61.81, down 3.18%, and has underperformed the sector significantly. The company faces ongoing financial struggles, including declining sales and profits, weak debt servicing ability, and reduced promoter confidence, contributing to its persistent stock decline.

As of 25-Mar, Aarey Drugs & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 61.81, which reflects a change of -2.03 (-3.18%). The stock has underperformed the sector by 5.68% today and has touched an intraday low of Rs 61, indicating a significant drop of 4.45%. <BR><BR>Over the past week, the stock has decreased by 14.79%, while the benchmark Sensex has only fallen by 1.87%. In the last month, the stock has also declined by 13.43%, compared to an 8.51% drop in the Sensex. This trend of underperformance is further highlighted by the fact that Aarey Drugs is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a persistent downward momentum.<BR><BR>The company has reported negative financial results for the last four consecutive quarters, with net sales falling by 27.92% and a staggering decline in profit before tax of 552.78%. Additionally, the company's ability to service its debt is weak, as indicated by a poor EBIT to interest ratio of 1.90. The return on equity is also low at 4.20%, signifying limited profitability per unit of shareholders' funds. <BR><BR>Moreover, there is a concerning trend of reducing promoter confidence, as promoters have decreased their stake in the company by 5.74% over the previous quarter. This reduction may signal a lack of confidence in the company's future prospects, contributing to the stock's decline. <BR><BR>Overall, the combination of poor financial performance, weak fundamentals, and diminishing promoter confidence are key factors driving the stock price of Aarey Drugs & Pharmaceuticals Ltd lower.

Which are the latest news on Aarey Drugs?